Molecular Partners

• NCT05673057

  Phase 1, Completed, 80 people, 6 Jan 2023

• TP53-mutant CHIP defines a pro-inflammatory phenotype and predicts adverse outcomes after CAR T-cell therapy

  Consulting or advice, 24 Aug 2026

• Immunosuppressive macrophages determine the effect of cellular senescence on tumor progression

  Grants or research support, 1 Jan 2026

Sources: pubmed.ncbi.nlm.nih.gov